Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clarithromycin
Drug ID BADD_D00480
Description Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Indications and Usage An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
Marketing Status approved
ATC Code J01FA09
DrugBank ID DB01211
KEGG ID D00276
MeSH ID D017291
PubChem ID 84029
TTD Drug ID D0Z1ZM
NDC Product Code 49452-2112; 46708-344; 46708-345; 57237-044; 61919-643; 71335-1493; 0781-6023; 65096-0100; 53002-7561; 65862-226; 0527-1932; 76420-051; 27241-064; 43063-530; 68071-5045; 68788-8480; 0527-1930; 57237-045; 60687-435; 63187-376; 63187-625; 71335-1567; 38779-1937; 63415-0018; 43063-942; 53002-7562; 62332-345; 68788-7933; 0527-1931; 62991-2687; 51655-668; 65862-225; 0781-6022; 43666-0001; 60592-429; 50090-5285; 67296-1072; 67296-1360; 68071-3116; 70518-2773; 71335-0017; 72189-299; 0781-1961; 15894-0026; 27241-065; 62135-615; 62135-616; 62332-344; 0591-2805; 59566-0123; 50090-5282; 50268-178; 50268-179; 64380-906; 67296-0464; 68071-2869; 0781-1962; 43063-752; 43063-823; 64380-905; 68788-7125; 0904-6872; 43781-0403; 51552-1566; 50090-1830
UNII H1250JIK0A
Synonyms Clarithromycin | 6-O-Methylerythromycin | TE-031 | TE 031 | TE031 | A-56268 | A 56268 | A56268 | Biaxin
Chemical Information
Molecular Formula C38H69NO13
CAS Registry Number 81103-11-9
SMILES CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N( C)C)O)(C)OC)C)C)O)(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal failure20.01.03.005--Not Available
Renal pain20.02.03.0030.000335%Not Available
Respiratory acidosis22.02.02.004; 14.01.04.0020.000223%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000558%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001787%
Respiratory tract haemorrhage22.02.07.011; 24.07.01.0360.000223%Not Available
Restlessness19.11.02.002; 17.02.05.0210.000893%
Retching07.01.07.0020.001117%Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.000223%
Rhabdomyolysis15.05.05.0020.002010%
Rheumatoid arthritis15.01.03.001; 10.04.06.0010.000447%Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.021--
Salivary hypersecretion07.06.01.0090.000223%Not Available
Screaming19.04.02.020; 08.01.03.099--Not Available
Scrotal oedema21.12.02.0010.000893%Not Available
Seizure17.12.03.001--
Sense of oppression08.01.09.0200.000223%Not Available
Sensory disturbance17.02.07.0060.000447%Not Available
Sensory loss17.02.07.0070.000447%Not Available
Serum sickness-like reaction10.01.03.005; 08.01.03.0030.000670%Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.001228%Not Available
Skin irritation23.03.04.009--Not Available
Skin lesion23.03.03.0100.000893%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.001318%Not Available
Sleep disorder19.02.04.0010.001452%Not Available
Sleep paralysis19.02.02.004; 17.15.02.0050.000491%Not Available
Sleep terror19.02.03.008; 17.15.02.0060.000223%Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene